# NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

> **NCT04170985** · — · COMPLETED · sponsor: **Illumina, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Neurologic Deficits
- Neurologic Disorder
- Neurologic Abnormalities

## Interventions

- **OTHER:** clinical Whole Genome Sequencing

## Key facts

- **NCT ID:** NCT04170985
- **Lead sponsor:** Illumina, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-18
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170985, "NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04170985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*